Abstract 5254: CARMIL3 promotes tumor progression in triple negative breast cancer: A possible novel biomarker

Abstract

Abstract Purpose: CARMIL3 (LRRC16B, capping protein regulator and myosin 1 linker 3) was previously identified as a novel oncofetal-like gene. It influences cell proliferation, cell cycle control and transformation, possibly mediated by cyclin B1. This study aimed to investigate the function of CARMIL3 in triple negative breast cancer (TNBC) cells and tissues. Methods: CARMIL3 mRNA was measured using a qRT-PCR in breast cancer cells (MDA-MB-231, MCF7, SK-BR3 and T-47D) and tissues from 20 patients with TNBC. The effects of CARMIL3 on cell proliferation, migration, and invasion were determined using MTT, wound healing, and Matrigel Transwell assays. Results: Results showed that, the CARMIL3 mRNA expressions were significantly increased in breast cancer cell lines, especially in triple negative breast cancer cell lines (MDA-MB-231 and MDA-MB-468) when compared to normal breast epithelial cells (MCF10A). Downregulation of CARMIL3 inhibited the cell proliferation, migration and invasion of MDA-MB-231. Furthermore, high CARMIL3 mRNA expression was found in 20 TNBC specimens than normal controls (p<0.0001). Conclusions: In conclusion, CARMIL3 expression in TNBC affects cancer progression, which suggests that CARMIL3 can be a new biomarker for patients with TNBC. Citation Format: Jeeyeon Lee, Dong Won Baek, Soo Jung Lee, Jae-Hwan Jeong, In Hee Lee, Jin Hyang Jung, Ho Yong Park, Yee Soo Chae, Jieun Kang. CARMIL3 promotes tumor progression in triple negative breast cancer: A possible novel biomarker [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5254.